• Publications
  • Influence
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head
PURPOSE We have previously demonstrated high locoregional control rates in patients with poor-prognosis head and neck cancer using fluorouracil (5-FU), hydroxyurea (HU), and concomitant radiotherapyExpand
  • 68
  • 2
A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer.
BACKGROUND 9-Aminocamptothecin (9-AC) is a synthetic analogue of camptothecin. Phase I studies, identified the maximum tolerated dose as 1416 micrograms/m2/day x 3 as continuous intravenous infusionExpand
  • 34
  • 1
Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer.
PURPOSE This multicenter phase II trial investigated the efficacy and safety of a combination of paclitaxel and topotecan in patients with pretreated metastatic breast cancer. Plasma levels ofExpand
  • 15
ADVISORY COMMITTEE ON NOVEL FOODS AND PROCESSES APPLICATION FOR THE APPROVAL OF LYCOPENE-RICH OLEORESIN FROM TOMATO UK OPINION
On 7 September 2004, the UK Competent Authority accepted an application from Berry Ottaway & Associates Ltd (UK) on behalf of LycoRed (Israel) for a lycopenerich oleoresin derived from tomato as aExpand
Initial Assessment of the Application for the Approval of Calcium-L-Methylfolate under the Novel Food Regulation (EC) No
The novel ingredient is chemically synthesised from folic acid and glucosamine hydrochloride and is intended to be used as an alternative source of folate in food supplements in accordance withExpand
R&D Programmes of the European communities in biotechnology and related areas
The research programme BRIDGE ‐ Biotechnology Research for Innovation, Development, and Growth in Europe ‐ the “successor of BEP (Biomolecular Engineering Programme 1982–1986) and BAP (BiotechnologyExpand